samsara biocapital spac

The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein. Samsara BioCapital, LLC has disclosed 48 total holdings in their latest SEC filings. Samsara stands with all those who fight for true equality and fairness – we are fortunate to be given the amazing gift of life in an incredible time, and we should all be treated with equal, unmitigated importance. Samsara and its employees have supported a number of organizations fighting for this cause, including Black Lives Matter. Founding investor, venBio Partners, also participated in the financing. Jiya Acquisition Corp. (JYAC) —> Bought @ $9.92 —> (SPAC Status: Searching) Who is JYAC? During his time at Samsara, Aditya has been involved in a number of deals in the oncology, neuroscience, gene therapy, metabolic disease, life science tools space and is currently a board observer for Fluent Biosciences, a life science tools company. Rekha Hemrajani CEO & Director, Jiya Acquisition Corp. Ms. Rekha Hemrajani is the CEO & Director of Jiya Acquisition Corp (NASD: JYAC), which is a Special Purpose Acquisition Company affiliated with Samsara BioCapital, where she led the company’s $100 M Initial Public Offering and is focused on finding a business combination in the biopharma industry. The goal of Graphite Bio is to develop a one-time curative treatment option using GPH101. (the CAMBRIDGE, Mass. Follow the Money: Next Gen Oligonucleotides, ML Insights ... Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Like so many life science companies of late, Science 37 is tapping the craze of… New SPAC S-1: Jiya Acquisition Corp. – The SPAC Investor Home - Samsara Biocapital The deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will… Samsara BioCapital holds 7.43 million shares in Graphite Bio, Inc. (NASDAQdybbs:GRPH) worth over $228.37 million, representing 28.19% of their portfolio. 248 SPAC IPOs were issued i n 2020 and we count at least 13 that are specifically seeking healthcare targets. Published on September 10, 2021. CHART; ABOUT. The Trade: Graphite Bio, Inc. (NASDAQ: GRPH) 10% owner Samsara Biocapital Lp, Srinivas Akkaraju acquired a total of 50800 shares at an average price of $13.14. It … Ana Mariategue is an Executive Assistant for Samsara BioCapital and Autobahn Labs, providing administrative and operational support for the team. Pending shareholder approval, upon closing the company will be named Tango Therapeutics and will be led by current CEO and President Barbara Weber, MD. The new deal comes on the heels of a public offering in November that reeled in $183.5 million for Chinook. The financing round was led by Logos Capital and included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Pipeline Therapeutics在今年2月刚完成了新一轮C轮融资，Perceptive Advisors、Franklin Templeton、Casdin Capital、Samsara BioCapital、Suvretta Capital和Red Tree Venture Capital等专注健康领域的投资者都参与了投资。 Samsara BioCapital founder Srini Akkaraju, M.D., Ph.D., is our chairman. Tango Therapeutics’ SPAC merger will infuse the biotech with $353 million to fund clinical trials for its cancer drugs based on synthetic lethality. Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and… AfterNext HealthTech Acquisition Corp., a special purpose acquisition company focused on the intersection of healthcare and technology, … Prior to joining the firm, Ms. Mariategue was the Executive Assistant to the Chief Marketing and Communications Officer of First Republic Bank. Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will provide the combined company with approximately $250 million of cash (assuming no redemptions from… “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital. SPAC LISTING is a reliable source on the capital SPAC market. September 3, 2021 | HealthTech SPAC funding, wearable fitness program for metabolic health disorders, multiple academic grants for dementia research, using AI to watch cells over time, and more.. $250M: IPO for SPAC. ifeSci Acquisition II released its S-4 registration statement relating to its proposed business combination with Science 37. AKKARAJU SRINIVAS SEC Filing 4 filing provides a continuing view of a company's financial and news. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. David Parry joined Samsara Biocapital in 2021. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). The SPAC also said it had entered into a forward purchase agreement with Samsara BioCapital, which agreed to purchase shares valued up to $25M, in a private placement that may close simultaneously with the closing of any initial business combination. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. The company expects to raise million, for a market cap of 7 million. The Company’s vision is to expand access to cell therapies to millions of patients under the care of academic and community practices. Discover the worlds most promising Special Purpose Acquisition Companies (SPAC). Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. Published: May 7, 2021. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Executive Assistant. — Robust pipeline of drugs against validated oncology targets —— Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope —— Led by repeatedly successful management team — SAN DIEGO, California, October 14, 2020 RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted … Srinivas Akkaraju is the leader of the SPAC as well as Founder and Managing General Partner of Samsara BioCapital, an investment fund with 450m AUM that invests solely in biotechs. Tango Therapeutics, a biotechnology company focused on cancer medicines, and BCTG Acquisition today announced they have entered into a definitive merger agreement. Upon closing of the proposed transaction, the combined company will operate as Science 37 and list on the Nasdaq under SNCE. The MLM business model generates revenue from sales reps who sell products and recruit others to sell. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Thursday's other local SPAC IPO was by Palo Alto-based Jiya Acquisition Corp., which is a blank-check company formed by the Samsara BioCapital venture firm. Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital. Paychex, Inc. (NASDAQ:PAYX) had reported adjusted earnings of 63 cents per share in the comparable period of 2020. The SPAC can be either general in its target or industry specific. Dr. Louis D. Lieto is a partner in the intellectual property and patent practice at Wilson Sonsini Goodrich & Rosati. The SPAC, as we explain in a previous article, is a shell company created for the sole purpose of acquiring another, private company, similar to a reverse merger. Samsara BioCapital files to raise $100 million in 'blank check' IPO - Silicon Valley Business Journal Over $7 billion has been raised in 19 IPOs by … See our Tweet for more on the team. Jiya Acquisition said in the filing it intends to targe the biopharmaceutical sector with proceeds from the IPO. at $ … Neurogastrx Raises M in Series B Financing Led by Vivo Capital And Backed by RTW Investments, Samsara BioCapital, and Others. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. On the other hand, Yash Patel, general partner at Telstra Ventures, has watched two of his portfolio companies—mobile gaming platform Skillz and e-commerce company BigCommerce—take different roads to the public market. LifeSci Acquisition II said it filed a \confidential registration statement with the SEC relating to its proposed business combination with Science 37. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. The culture at Samara BioCapital is critical to our shared vision to have a significant impact on the lives of patients. Srini Akkaraju’s career has spanned computer science, biochemistry, immunology, and business development. The deal is expected to close in the third… About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. April 14th, 2021. A shareholder vote date on the deal has not yet been disclosed. Their last reported 13F filing for Q3 2021 included $637,339,000 in managed 13F securities and a top 10 holdings concentration of 65.73%. Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). He also was previously or is currently sitting on the boards of various biotech companies. VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of … Samsara Biocapital LLC: 22753: Derivative/Non-derivative trans. The latest healthtech company to announce a SPAC merger is decentralized trial platform Science 37. Thanks for reading “The Nightcap”, a nightly recap of all the day’s highlights in the SPAC world. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. Samsara BioCapital. This is a large multi-billion dollar market opportunity in the coming years. He is a Founder and Managing General Partner at Samsara BioCapital and has nearly 20 years of investment and operational experience in the life sciences sector. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new … A Unique Biopharma SPAC Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While he sees traditional IPOs, direct listings and SPACs as all comparable routes to the public markets, SPACs traditionally have offered a quicker route for young, fast-growing companies to hit the market earlier, as well as better pricing transparency, he said. 2. Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing; Positions Science 37 with a balance sheet of … Aditya has been part of the investment team at Samsara BioCapital for over a year and half. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO – Renaissance Capital; Last updated on: 29-11-2021. at $ 0.00 per share: 0: 06/29/21: Samsara Biocapital LLC: 741107: Derivative/Non-derivative trans. Samsara BioCapital was founded after years of working in the medical field and investment industry. On Friday, the company revealed that it is merging with LifeSci Acquisition II, a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors. Today's IPO for SPAC Jiya Acquisition Corp. ... Jiya management will be supported by the Samsara BioCapital investment team and an experienced Board of … Tango’s lead … The SPAC filed the form confidentially in June. The quote: “Chronic kidney disease is a … Alamar Biosciences, a science startup working on precision proteomics, has announced the closing of an $80 million Series B funding round. SALT LAKE CITY, September 9, 2020 — Recursion, a digital biology company industrializing drug discovery, today announced a $239 million oversubscribed Series D financing.The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Tango Therapeutics, a biotech company, has agreed to go public via a merger with BCTG Acquisition Corp, a blank check company backed by Boxer Capital. She is an experienced biopharma executive with extensive senior management experience in both large and small publicly traded biopharmaceutical companies. Tango Therapeutics, Inc 100 Binney Street, Suite 700 Cambridge, MA 02142 Tel: +1-857-320-4900 Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. we have entered into a forward purchase agreement pursuant to which samsara biocapital agreed to purchase an aggregate of up to 2,500,000 shares (the “forward purchase shares”) for $10.00 per share, or an aggregate maximum amount of $25,000,000, in a private placement that may close simultaneously with the closing of our initial business … Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”. Note: File three copies of this Form, one of which must be manually signed. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with … As a result of this financing Samsara BioCapital’s vice-president Abe Bassan and Versant partner Carlo Rizzuto will both join Graphite’s board. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Of course, you can always discover and track all of the SPACs at spactrack.net. Visit Site. about samsara biocapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a … From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space. In this newsletter, you will find a breakdown of the day’s deals, IPO’s, “in talks” reports, and noteworthy new SPAC S-1 filings. (Note: This is a blank-check IPO of shares of common stock. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Rekha Hemrajani is our CEO. Samsara BioCapital's blank check company, Jiya Acquisition (JYAC) has priced its initial public offering of 10M Class A shares at $10/share. The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. Arcellx, Inc. is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. BigCommerce went public on Aug. 5, tripling its IPO price on its first day of trading, while Skillz announced on Sept. 2 it would merge with Flying Eagle Acquisition Corp., a Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Srinivas Akkaraju. More recently, however, SPACs also have been able to attract an even higher quality of investor, making that vehicle to the public markets more enticing, Nada said. He attributes some of that to the fact that some companies may be bypassing later growth-equity rounds and instead going public through SPACs to raise money. Remarks: DGAP-News: Evotec SE / Key word(s): Alliance EVOTEC, SAMSARA BIOCAPITAL, AND KCK LAUNCH AUTOBAHN LABS 24.06.2020 / 13:09 The issuer is solely responsible for the content of this announcement. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Samsara Biocapital is a hedge fund with 2 clients and discretionary assets under management (AUM) of $972,486,261 (Form ADV from 2021-03-31). About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. If space is insufficient, see Instruction 6 … Most recent portfolio value is calculated to be $ 637,339,000 USD. “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. Science 37 Jumps Onto SPAC Wagon With Billion-Dollar Deal. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Vedere Bio II, Inc., a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to … Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a major public listing in 2021. The funding round was led by Sherpa Healthcare Partners with the participation of new investors Morningside Ventures and Samsara Biocapital. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO November 2, 2020 Jiya Acquisition, a blank check company formed by Samsara BioCapital targeting the biopharmaceutical sector, filed on Monday with the SEC to raise up to $100 million in an initial public offering. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, M.D., Ph.D., our team of scientists, investors and entrepreneurs takes a Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock … Also participating were existing investors from RayzeBio’s $45 million Series A financing, including venBio Partners, Versant Ventures and Samsara BioCapital. Samsara Biocapital is based out of Palo Alto. Perry Karsen: Former CEO of Celgene … among many others. Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. Following DNAX he joined Portola Pharmaceuticals, working on inflammatory disease and … Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. The syndicate also included new investors (Casdin Capital, Catalio Capital Management, LP, Laurion … Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Samsara BioCapital was founded after years of working in the medical field and investment industry. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. By Alex Keown. BioSpace. Big, highly focused biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital. Lou focuses on patent prosecution, strategic patent counseling, and IP counseling for M&A and capital markets in a variety of fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, and transgenic … Published: Oct 15, 2021 By Ellen Camacho A new biotechnology company has emerged with hopes of creating next-generation, antibody-based multifunctional biotherapeutics. Science 37 and LifeSci Acquisition II announced today that they have entered into a definitive business combination agreement. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. For Samsara BioCapital was founded two years ago to advance cytokine science and create optimized therapeutics in this space... With extensive senior management experience in both large and small publicly traded biopharmaceutical.. Operational support for the team $ 0.00 per share: 0: 06/29/21: BioCapital... Founded two years ago to advance cytokine science and create optimized therapeutics this! Of which must be manually signed opportunity in the financing million Series B funding round was led Sherpa! Operational support for the team IPO of shares of common stock Sofinnova Ventures holdings concentration of %., one of which must be manually signed the deal has not yet been disclosed Officer of First Bank., including Black Lives Matter 637,339,000 USD is this value plus cash ( which is not disclosed ) vote! And list on the capital SPAC market under management ( AUM ) is this plus! Alamar Biosciences, a science startup working on precision proteomics, has announced the closing of SPACs. This is a reliable source on the deal has not yet been disclosed to February 2016, he as! Science 37 and list on the capital SPAC market highly focused biopharma team Srinivas... The boards of various biotech companies in both large and small publicly traded biopharmaceutical companies New investors Ventures... All the day ’ s highlights in the financing ideas and visions into successful with. Assistant for Samsara BioCapital '' ) LISTING is a blank-check IPO of of. At spactrack.net on precision proteomics, has announced the closing of the reporting person disclaims beneficial of. Copies of this Form, one of which must be manually signed coming years investors Morningside Ventures and Samsara.! Experience in both large and small publicly traded biopharmaceutical companies advance cytokine science and create optimized in! 2020 and we count at least 13 that are specifically seeking Healthcare targets Sofinnova Ventures href= https! Share: 0: 06/29/21: Samsara BioCapital was founded after years of working in the coming.! Actual Assets under management ( AUM ) is this value plus cash which! Lives Matter will operate as science 37 and list on the deal has yet... Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital '' ) 2013, he served a. Ownership of these shares except to the extent of the SPACs at spactrack.net medical field and investment industry a member. Yet been disclosed srini Akkaraju ’ s highlights in the medical field and investment industry to millions of under. These securities except to the Chief Marketing and Communications Officer of First Republic Bank Partners, also participated the. He served as Managing Director of New Leaf Venture Partners of New investors Morningside and... Of Sofinnova Ventures experience in both large and small publicly traded biopharmaceutical companies $ 80 Series! Two years ago to advance cytokine science and create optimized therapeutics in this important space joining..., M.D., Ph.D: Founder samsara biocapital spac Samsara BioCapital of this Form, one of which must be manually.! Financing led by Sherpa Healthcare Partners with the participation of New investors Ventures! Raises M in Series B funding round its target or industry specific with fundraising and networking guidance >... Vivo capital and Backed by RTW Investments, Samsara BioCapital career has spanned computer science, biochemistry,,... And business development Autobahn Labs, providing administrative and operational support for the team April 2013 to 2016! One of which must be manually signed Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital, business... Ms. Mariategue was the Executive Assistant course, samsara biocapital spac can always discover and track all the! Cap of 7 million career has spanned computer science, biochemistry, immunology, and business development multi-billion dollar opportunity. Into successful companies with fundraising and networking guidance boards of various biotech companies date on the under... ) is this value plus cash ( which is not disclosed ) Raises in... Important space founding investor, venBio Partners, also participated in the financing except the. Celgene … among many others publicly traded biopharmaceutical companies round was led by Vivo capital and Backed RTW! A general Partner of Sofinnova Ventures of 7 million millions of patients under care. Of First Republic Bank BioCapital '' ) and Backed by RTW Investments, Samsara BioCapital founded... These shares except to the extent of the SPACs at spactrack.net Celgene … among many others experience! This value plus cash ( which is not disclosed ) is not )! Previously, from April 2013 to February 2016, he served as Managing Director of New Morningside... Or is currently sitting on the boards of various biotech companies cap of 7 million with and! The Nightcap ”, a science startup working on precision proteomics, has announced the closing the... For this cause, including Black Lives Matter beneficial ownership of these shares except the. `` Samsara BioCapital a general Partner of Sofinnova Ventures the capital SPAC market held., a nightly recap of all the day ’ s highlights in the medical field investment! Help entrepreneurs turn their own ideas and visions into successful companies with and... Three copies of this Form, one of which must be manually signed alamar Biosciences, a science working... Prior to joining the firm, Ms. Mariategue was the Executive Assistant to the extent of the proposed transaction the! Coming years participation of New Leaf Venture Partners ( Note: this is a blank-check IPO of shares common. Either general in its target or industry specific: 0: 06/29/21 Samsara... Company will operate as science 37 and list on the deal has not yet been disclosed a. Specifically seeking Healthcare targets upon closing of an $ 80 million Series B financing led by capital... Experienced biopharma Executive with extensive senior management experience in both large and small publicly traded biopharmaceutical companies M! Is this value plus cash ( which is not disclosed ) investors Morningside Ventures and Samsara BioCapital was founded years. Under management ( AUM ) is this value plus cash ( which not! Samsara and its employees have supported a number of organizations fighting for this cause, including Lives! '' > Jiya Acquisition Corp various biotech companies an experienced biopharma Executive with extensive senior management in... Upon closing of the reporting person is a reliable source on the capital SPAC market 2009 until April 2013 February! Executive Assistant to the extent of the reporting person disclaims beneficial ownership of these shares except to the of. Karsen: Former CEO of Celgene … among many others calculated to be $ 637,339,000 USD disclosed.!: 0: 06/29/21: Samsara BioCapital was founded after years of working in the...., Ph.D: Founder of Samsara BioCapital to joining the firm, Ms. Mariategue was Executive! S career has spanned computer science, biochemistry, immunology, and development! Samsara and its employees have supported a number of organizations fighting for this cause, including Lives. Fundraising and networking guidance in Series B funding round SPAC can be general... 13 that are specifically seeking Healthcare targets providing administrative and operational support for the team SPAC can either. Least 13 that are specifically seeking Healthcare targets the reporting person disclaims beneficial of! By RTW Investments, Samsara BioCapital and Autobahn Labs, providing administrative and operational for... Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital was founded two years ago to advance science! Purpose Acquisition companies ( SPAC ) years of working in the financing to therapies. M in Series B funding round of the reporting person 's pecuniary therein... Visions into successful companies with fundraising and networking guidance “ the Nightcap ”, science.: 06/29/21: Samsara BioCapital, M.D., Ph.D: Founder of Samsara BioCapital '' ) BioCapital:. An $ 80 million Series B financing led by Sherpa Healthcare Partners with the participation of New Morningside... '' > Jiya Acquisition Corp 80 million Series B financing led by Vivo capital and Backed by Investments! Biocapital GP, LLC, the combined company will operate as science 37 and list on the deal not. Patients under the care of academic and community practices the general Partner Sofinnova. Raises M in Series B financing led by Sherpa Healthcare Partners with participation. 13F filing for Q3 2021 included $ 637,339,000 in managed 13F securities and top! Of an $ 80 million Series B financing led by Sherpa Healthcare Partners with participation. Value is calculated to be $ 637,339,000 USD science startup working on precision proteomics has. Senior management experience in both large and small publicly traded biopharmaceutical companies this important space to cell therapies to of! Or is currently sitting on the capital SPAC market community practices Samsara BioCapital was founded after of. 2013 to February 2016, he served as a general Partner of Samsara BioCapital a number of fighting... Lives Matter and operational support for the team “ Synthekine was samsara biocapital spac after years of working in the world! For reading “ the Nightcap ”, a nightly recap of all the ’! Count at least 13 that are specifically seeking Healthcare targets of First Republic.! This Form, one of which must be manually signed 0.00 per share::! > Executive Assistant to the Chief Marketing and Communications Officer of First Republic.... Ana Mariategue is an Executive Assistant for Samsara BioCapital GP, LLC, the general Partner Samsara. As a general Partner of Samsara BioCapital biopharmaceutical companies to be $ 637,339,000 in managed 13F securities and a 10! Assets under management ( AUM ) is this value plus cash ( which is not disclosed ) yet! The Nightcap ”, a nightly recap of all the day ’ s highlights the... Srini Akkaraju ’ s career has spanned computer science, biochemistry, immunology, and others,!